The Resurgence and Clinical Development of Influenza A in Pediatric Populations in China: Changes in Epidemiology and Serological Patterns from Pre-Pandemic to Post-Pandemic Periods (2019–2023) - Top-Institutions - MDSpire

The Resurgence and Clinical Development of Influenza A in Pediatric Populations in China: Changes in Epidemiology and Serological Patterns from Pre-Pandemic to Post-Pandemic Periods (2019–2023)

  • By

  • Guiling Xu

  • Yu Chen

  • Yu Zhu

  • Qing Fang

  • Xiaotong Xue

  • Kejun Hu

  • Sha Zhou

  • Li Hong

  • Ying Xiang

  • January 17, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Shanghai Children's Medical Center
    Shanghai Children's Medical Center

    Shanghai, China

    Key Differentiators

    • Pediatric Infectious Diseases
    • Epidemiology
    • Clinical Virology

  • #2

    Centers for Disease Control and Prevention (CDC) - Influenza Division
    Centers for Disease Control and Prevention (CDC) - Influenza Division

    Atlanta, GA

    Key Differentiators

    • Infectious Disease Epidemiology
    • Public Health Surveillance
    • Vaccine Research

  • #3

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Infectious Diseases
    • Vaccine Development

  • #4

    Children’s Hospital of Philadelphia (CHOP)
    Children’s Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Infectious Diseases
    • Clinical Research
    • Immunology

  • #5

    University of Hong Kong - School of Public Health
    University of Hong Kong - School of Public Health

    Hong Kong, China

    Key Differentiators

    • Epidemiology
    • Infectious Diseases
    • Public Health

Original Source(s)

The Resurgence and Clinical Development of Influenza A in Pediatric Populations in China: Changes in Epidemiology and Serological Patterns from Pre-Pandemic to Post-Pandemic Periods (2019–2023)

  • by Guiling Xu, Yu Chen, Yu Zhu, Qing Fang, Xiaotong Xue, Kejun Hu, Sha Zhou, Li Hong, Ying Xiang

  • January 17, 2026

Related Content

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

CXCR3 ameliorates neutrophil-dependent disease severity in SARS-CoV-2 infection by regulating CD4+ T cell recruitment